Brown adipose tissue

Vice Health and Wellness Signs Letter of Intent to Advance Scientific Technology Solutions for Weight Loss and Obesity

Retrieved on: 
Thursday, August 24, 2023
OTC Markets Group, BAT, Partnership, Obesity, CSE, Brown adipose tissue, Weight loss, Health, Stevia, GLP1, FSE, Research, LOI, Creativity, Alternative medicine, Literature, Z24, Blood, Hunger, VICE, HSL, Health Canada, Pharmacology, Wellness, Sewage treatment, Dietary supplement, Biologic, Ketogenesis

It is a unique and ground-breaking technology that facilitates efficient fat metabolism and energy production.

Key Points: 
  • It is a unique and ground-breaking technology that facilitates efficient fat metabolism and energy production.
  • Biologic Pharmamedical will provide scientific backing, literature, and relevant research findings to substantiate health claims associated with the products.
  • Furthermore, Biologic Pharmamedical will assist Vice Health and Wellness in organizing digital seminars or speaking engagements to disseminate vital information about the products.
  • In addition, Vice Health and Wellness supplements will be enriched with Glyvia™, a patented and Health Canada approved natural product.

BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event

Retrieved on: 
Tuesday, January 17, 2023
Regenerative medicine, Brown adipose tissue, Pharmaceutical industry

Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit.

Key Points: 
  • Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit.
  • During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology.
  • The company is currently engaged in a Phase 2 trial in Chronic Lumbar Disc Disease, and advancing other programs with BRTX100 and with Brown Adipose Tissue.

BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem® Program

Retrieved on: 
Monday, March 22, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Connective tissue, Cell biology, Developmental biology, Adult stem cell, Adipose tissue, Brown adipose tissue, Stem cell transplantation for articular cartilage repair

The notices of allowance were for a total of three patent applications and covered the United States, Israel, France, Germany, Italy, Spain, and the United Kingdom.

Key Points: 
  • The notices of allowance were for a total of three patent applications and covered the United States, Israel, France, Germany, Italy, Spain, and the United Kingdom.
  • These patent allowances will allow for the protection of a specific isolated human brown adipose tissue-derived stem cell capable of differentiating into multiple cell types and their applications.
  • Our ThermoStem Program is a platform technology that we expect will create a valuable therapeutic pipeline for BioRestorative.
  • BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity

Retrieved on: 
Wednesday, March 10, 2021
Diabetes, University, Stem cells, Pharmaceutical, Education, General Health, Seniors, Cardiology, Science, Biotechnology, Alternative medicine, Consumer, Other Science, Health, Research, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Connective tissue, Stem cells, Obesity, Adipose tissue, Cell therapy, Brown adipose tissue, Ischemia

We will be investigating the potential of human pluripotent stem cell-derived brown adipose tissue (BAT) to improve metabolic health and cardiac function, said Dr. Stanford.

Key Points: 
  • We will be investigating the potential of human pluripotent stem cell-derived brown adipose tissue (BAT) to improve metabolic health and cardiac function, said Dr. Stanford.
  • We are delighted to collaborate with Dr. Kristin Stanford, who has dedicated her career to understanding brown adipose tissue (BAT).
  • The research could generate proof-of-concept data in an animal model for AgeXs BAT cell therapy candidate AgeX-BAT1, said Dr. Nafees Malik, Chief Operating Officer of AgeX.
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program

Retrieved on: 
Thursday, December 12, 2019
Connective tissue, Brown adipose tissue

This is the eighth patent issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).

Key Points: 
  • This is the eighth patent issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).
  • We continue to drive innovative and novel technology focusing on transformative therapies for our brown fat program, said Mark Weinreb, CEO of BioRestorative Therapies.
  • We are pleased to add to our intellectual property library this recently issued patent by the Israeli Patent Office for our metabolic program to help power disruptive ways to treat metabolic disorders.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program

Retrieved on: 
Wednesday, October 23, 2019
Branches of biology, Biology, Life sciences, Connective tissue, Obesity, Biotechnology, Cell biology, Brown adipose tissue, Adipose tissue, Stem cell, Adult stem cell, Ciberobn

This is the second patent issued for the Companys brown fat technology in Australia and adds to three other patents related to BioRestoratives metabolic program (ThermoStem Program) that have previously been issued to the Company in the United States and other countries.

Key Points: 
  • This is the second patent issued for the Companys brown fat technology in Australia and adds to three other patents related to BioRestoratives metabolic program (ThermoStem Program) that have previously been issued to the Company in the United States and other countries.
  • This patent, granted by the Australian Patent Office for our metabolic program, adds to our growing family of IP surrounding and protecting our brown fat metabolic cell program, said Mark Weinreb, CEO of BioRestorative Therapies.
  • BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
  • Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT).